Literature DB >> 1953225

Barrett's esophagus. Prevalence and incidence of adenocarcinoma.

W A Williamson1, F H Ellis, S P Gibb, D M Shahian, H T Aretz, G J Heatley, E Watkins.   

Abstract

Between January 1973 and January 1989, 241 patients with Barrett's esophagus were treated at the Lahey Clinic Medical Center, Burlington, Mass. Of these patients, 65 presented with adenocarcinoma in Barrett's esophagus for a prevalence rate of 27%. Of 176 patients followed up for a total of 497 patient-years, adenocarcinoma developed in five patients for an incidence of one per 99 patient-years. The development of adenocarcinoma during endoscopic surveillance 1, 2, 2, 4, and 10 years after the initial diagnosis of Barrett's esophagus emphasizes the importance of long-term endoscopic and histologic surveillance. All five patients had severe dysplasia before adenocarcinoma developed. Yearly endoscopic follow-up examination is recommended for all patients with Barrett's esophagus unless mild dysplastic changes are found, in which case surveillance should be increased. Patients with severe dysplasia who are otherwise acceptable candidates for operation should be advised to have esophageal resection.

Entities:  

Mesh:

Year:  1991        PMID: 1953225     DOI: 10.1001/archinte.151.11.2212

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  50 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  Barrett's oesophagus.

Authors:  R M Navaratnam; M C Winslet
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

3.  Expression of inducible nitric oxide synthase in human gastric cancer.

Authors:  Yu Jun; Guo Fei; Matthias P A Ebert; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

4.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

Review 5.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 6.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

7.  Giant adenoma arising in the lower esophagus with adenocarcinoma.

Authors:  Shih-Yuan Fang; Chin-Yen Wu; Heng-Chung Chen; Yi-Chieh Lin; Yi-Ying Wang; Hsin-Yuan Fang
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 8.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

9.  The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data.

Authors:  T J Hayeck; C Y Kong; S J Spechler; G S Gazelle; C Hur
Journal:  Dis Esophagus       Date:  2010-03-26       Impact factor: 3.429

10.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.